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4T Treating to Target in Type 2 Diabetes
To the Editor: We welcome the opportunity to comment on the issues raised by Wägner and Mauricio [1] concerning our systematic review [2] of different types of insulin treatment for patients with type 2 diabetes. Many of the issues raised in their letter were addressed in the review. The limited number of trials providing data for each comparison, and consequently the difficulty in drawing firm conclusions, is clearly stated in the Discussion. Eight of 22 trials scored five out of a possible six points in the modified assessment for potential bias; and the database search for the review was carried out in October 2008, 10 months before the results of the Treating to Target in Type 2 Diabetes (4-T) study 3 year data [3] were known. In carrying out this review, our intention was to report potential differences between insulin regimens used routinely in the treatment of type 2 diabetes. We observed smaller reductions in HbA 1c levels in patients using basal regimens compared with those using prandial or biphasic regimens. Lower insulin doses for patients using basal regimens were observed, but this does not imply that more aggressive titration would have resulted in more favourable outcomes at 1 year.
We note the suggestion that the time-point in the progression of diabetes may influence the choice of insulin regimen. Given the benefit of minimising the risk of hypoglycaemia, as demonstrated by the 4-T trial [3] , prompt response to oral therapy inadequacy with basal insulin should be recommended. That study has not, to date, provided evidence of benefit for individualising therapy based on markers of disease progression, although the different impact of the regimens reported by the 4-T trial may lead individual patients to prefer one therapy to another.
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